共 77 条
[1]
Siegel RL(2017)Cancer Statistics CA Cancer J Clin 67 7-30
[2]
Miller KD(2014)Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors Springerplus 3 535-347
[3]
Jemal A(2016)Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the carolina breast cancer study: a case-control study Breast Cancer Res 18 79-3314
[4]
Weide R(2009)Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease J Am Coll Surg 208 341-908
[5]
Feiten S(2016)Subtype-dependent relationship between young age at diagnosis and breast cancer survival J Clin Oncol 34 3308-306
[6]
Friesenhahn V(2014)Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting Oncologist 19 901-467
[7]
Heymanns J(2008)Second-line and third-line chemotherapy for lung cancer: use and cost Am J Manag Care 14 297-1601
[8]
Kleboth K(2013)Medical costs associated with use of systemic therapy in adults with colorectal cancer J Manag Care Pharm 19 461-1423
[9]
Thomalla J(2012)Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer JAMA 307 1593-197
[10]
Chollet-Hinton L(2016)Clinical and economic outcomes by first-line treatment among women with HR +/HER2- metastatic breast cancer in a large US health plan database Curr Med Res Opin 32 1417-1545